- 1	1				
1	Sandra A. Edwards (State Bar No. 154578) Joshua W. Malone (State Bar No. 301836)				
2	Farella Braun + Martel LLP 235 Montgomery Street, 17th Floor	ELECTRONICALLY			
3	San Francisco, CA 94104 Telephone: (415) 954-4400; Fax: (415) 954-448	05/24/2018			
4	sedwards@fbm.com jmalone@fbm.com				
5	Joe G. Hollingsworth (appearance <i>pro hac vice</i> )	Clerk of the Court BY:VANESSA WU			
6	Martin C. Calhoun (appearance <i>pro hac vice</i> ) Kirby T. Griffis (appearance <i>pro hac vice</i> )	Deputy Clerk			
7	William J. Cople (appearance <i>pro hac vice</i> ) Hollingsworth LLP				
8	1350 I Street, N.W. Washington, DC 20005				
9	Telephone: (202) 898-5800; Fax: (202) 682-163 jhollingsworth@hollingsworthlp.com	39			
10	mcalhoun@hollingsworthllp.com kgriffis@hollingsworthllp.com wcople@hollingsworthllp.com				
11					
12	James M. Hilmert (appearance <i>pro hac vice</i> ) Winston & Strawn LLP 35 West Wacker Drive Chicago, IL 60601 Telephone: (312) 558-5969; Fax: (312) 558-5700				
13					
14					
15					
16	Attorneys for Defendant				
17	MONSANTO COMPANY				
18	SUPERIOR COURT OF THE STATE OF CALIFORNIA				
19	COUNTY OF SAN FRANCISCO				
20					
21	DEWAYNE JOHNSON,	Case No. CGC-16-550128			
22	Plaintiff,	DEFENDANT MONSANTO COMPANY'S MOTION IN LIMINE NO. 7 TO EXCLUDE EMAIL FROM DONNA FARMER			
23	vs.				
24	MONSANTO COMPANY,				
25	Defendant.	Trial Date: June 18, 2018 Time: 9:30 a.m.			
26		Department: TBD			
27					
28					

34812\6689452.1

## I. <u>INTRODUCTION</u>

Defendant Monsanto Company ("Monsanto") respectfully requests that this Court exclude an email written by Donna Farmer to John Combest in 2009. This email is irrelevant, misleading and unfairly prejudicial to Monsanto and therefore inadmissible. *See* Cal. Evid. Code §§ 210, 350 and 352.

## II. BACKGROUND

Monsanto anticipates that Plaintiff will attempt to introduce into evidence a 2009 email from Donna Farmer, Ph.D., a product safety toxicologist for Monsanto, to John Combest, a member of the Monsanto public affairs group, to support Plaintiff's argument that Monsanto did not conduct safety tests on its formulated herbicide product, Roundup® and Ranger PRO®. In the September 21, 2009 email, Dr. Farmer stated to Mr. Combest that he could not "say that Roundup does not cause cancer...we have not done carcinogenicity studies with 'Roundup.'" Dr. Farmer's statement in this email, however, is taken out of context and does not reflect the numerous studies Monsanto and other researchers undertook to test the safety of the formulated products and their ingredients.

Monsanto's products have been the subject of repeated epidemiologic, animal, and genotoxicity studies, which have shown no evidence of carcinogenicity or mutagenicity in the final formulated glyphosate-containing pesticides. *See, e.g.*, Declaration of Sandra A. Edwards ("Edwards Decl.") at ¶ 5, Ex. 4 (Andreotti et al., *Glyphosate Use and Cancer Incidence in the Agricultural Health Study*, 110 J. Nat'l Cancer Inst. 1, 1 (2018)) ("In this large, prospective cohort study, no association was apparent between glyphosate and any solid tumors or lymphoid malignancies overall, including NHL and its subtypes."); Edwards Decl. at ¶ 6, Ex. 5 (Heydens et al., *Genotoxic Potential of Glyphosate Formulations: Mode-of-Action Investigations*, J. of Agricultural and Food Chemistry at p. 1 (2008)) ("A broad array of in vitro and in vivo assays has consistently demonstrated that glyphosate and glyphosate-containing herbicide formulations (GCHF) are not genotoxic. . . . results continue to support the conclusion that glyphosate and GCHF are not genotoxic under exposure conditions that are relevant to animals and humans."); Edwards Decl. at ¶ 7, Ex. 6 (De Roos et al., *Cancer Incidence Among Glyphosate-Exposed* 

34812\6689452.1

Pesticide Applicators in the Agricultural Health Study, 113 Environmental Health Perspectives 49, at 52-53 (2005)) ("[T]he available data provided evidence of no association between glyphosate exposure and NHL incidence."); Edwards Decl. at ¶ 8, Ex. 7 (Kier et al, Review of Genotoxicity studies of glyphosate and glyphosate-based formulations, Critical Reviews in Toxicology at p. 1 (2013)) (noting "earlier review of the toxicity of glyphosate and the original Roundup-branded formulation concluded that neither glyphosate nor the formulation poses a risk for the production of heritable/somatic mutations in humans," and finding that glyphosate and typical glyphosate-based formulations "do not appear to present significant genotoxic risk under normal conditions of human or environmental exposures").

While federal regulations did not require Monsanto to perform chronic carcinogenicity studies on its final formulated products, the company nonetheless did extensive "six-pack tests" on its products, in which acute oral, acute dermal, acute inhalation, skin and eye irritation and a skin sensitization exposure tests are performed. *See* Edwards Decl. at ¶ 9, Ex. 8 (Dep. of Donna Farmer ("Farmer Dep.") at 52:4-7)<sup>1</sup>; *id.* at 432-33 (testing demonstrated that Monsanto's products were "practically and slightly nontoxic . . . [with] very . . . low acute, dermal and inhalation toxicity [and] low eye and skin irritation . . ."). Monsanto has also undertaken genotoxicity and in vivo animal testing on the formulated products, neither of which were required by federal regulations. *See Id.* at 434-35.

The ingredients in Monsanto's products Roundup<sup>®</sup> and Ranger PRO<sup>®</sup>, i.e. glyphosate and the surfactants, have also been extensively studied and found to be non-carcinogenic. *See* Edwards Decl. at ¶ 10, Ex. 9 (Belvaux email, MONGLY01159775-78 (March 5, 2013)) (noting that impact of long term exposure to RoundUp<sup>®</sup> products "has been assessed according to the regulatory requirements in chronic and carcinogenicity studies conducted with the active ingredient glyphosate"); *see also* Edwards Decl. at ¶ 11, Ex. 10 (Email from Stephen Adams to Gary Klopf et al., MONGLY01155974-79 (Dec. 14, 2010)) (noting that while direct

<sup>&</sup>lt;sup>1</sup> *Id.* ("[W]e are not required to do chronic carcinogenicity studies on the formulated product, but we are on the active ingredient.").

carcinogenicity testing of the product formulations is unavailable, the company did "have such testing on the glyphosate component and some extensive tox testing on the surfactant. Since the glyphosate formulations are simply a blend of these components, I think we can address these questions in a confident manner."). EPA has further determined that the group of surfactants used in Monsanto's products are not neurotoxic, mutagenic, clastogenic, or carcinogenic. *See* Edwards Decl. at ¶ 12, Ex. 11 (EPA Memorandum Re: Alkyl Amine Polyalkoxylates (JITF CST 4 Inert Ingredients) at 4).

Because Monsanto's final formulated glyphosate-containing products and their ingredients have been extensively studied, Plaintiff's allegations to the contrary are unsupportable. As Dr. Farmer clarified during her deposition, "we have no evidence of carcinogenicity with glyphosate, we have no evidence with the surfactant," and therefore no evidence to suggest that Roundup<sup>®</sup> and Ranger PRO<sup>®</sup> cause cancer. Edwards Decl. at ¶ 9, Ex. 8 (Farmer Dep. at 51); *id.* at 468 ("[T]his should have been really that we have done carcinogenicity studies with glyphosate, but with Roundup we don't believe that it causes cancer based on the lack of carcinogenicity with glyphosate and lack of carcinogenicity within the surfactants."). For this reason alone, Dr. Farmer's email and out-of-context statement about the carcinogenicity testing of the products should be excluded as irrelevant. *See* Cal. Evid. Code § 210; *People v. De La Plane*, 88 Cal. App. 3d 223, 242 (1979), *cert. denied*, 444 U.S. 841 (1979), *disapproved on other grounds in People v. Green*, 27 Cal. 3d 1, 39 n.25 (noting that evidence that produces "only speculative inference" is irrelevant and thus inadmissible).

Furthermore, this email is a "soundbite" that would serve only to confuse and mislead the jury into punishing Monsanto for an erroneous perception that the product has not been tested. *See* Cal. Evid. Code §§ 350, 352. Allowing Plaintiff to put this email in front of the jury as evidence that Roundup® and Ranger PRO® causes cancer or that Monsanto failed to adequately test its products would be unduly prejudicial to Monsanto and likely to waste time and resources as Monsanto attempts to refute these misleading statements. *See Lemer v Boise Cascade, Inc.*, 107 Cal. App. 3d 1, 10 (1980) (excluding evidence when its "marginal value [is] more than outweighed by the heavy costs in trial time and expense" that would ensue). The ingredients and

- 1				
1	Monsanto's final formulated products have been thoroughly tested as required by the applicable			
2	regulations, and Plaintiff should not be permitted to put this email before the jury as evidence of			
3	inadequate testing.			
4	III.	CONCLUSION		
5		For the foregoing reasons, the Court should exclude this email.		
6				
7	Dated:	May 24, 2018	Respe	ectfully submitted.
8			FARE	ELLA BRAUN + MARTEL LLP
9			By:	Some Elevas
10				Sandra A. Edwards
11				neys for Defendant
12	MONSANTO COMPANY			
13				
14				
15				
16 17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				

Farella Braun + Martel LLP 235 Montgomery Street, 17th Floor San Francisco, California 94104 (415) 954-4400